Our laboratory headed by Prof. Dr. Mehmet Fatih Yanik is developing advanced technologies to communicate with and to non-invasively manipulate brain networks and subsequent cognitive behaviours for both fundamental studies and therapeutics of brain disorders. We are also developing cognitively challenging paradigms at the core of major brain disorders such as Autism and Schizophrenia; yet also important for robotics and AI where good computational models currently do not exist (such as imitation learning and inference of rule switching).
PROJECTS: We MAY have available projects in the lab for undergraduate, master's, PhD level students, and postdocs. Please contact Prof. Mehmet Fatih Yanik directly with your CV/transcript (yanik at ethz dot ch).
Bridge Discovery Award to Prof. Yanik’s team for pre-clinical large animal studies to translate non-invasive focal brain drug delivery technology to clinic
Treatment of brain disorders such as depression, chronic anxiety, obsessive compulsivity, schizophrenia, and epilepsy remain a formidable challenge despite the significant advances made in our understanding of the basic neurobiology. In addition to reasons for therapeutic failures specific to each brain disorder, there is a common underlying problem: Brain disorders often originate from dysfunctions of specific brain regions and circuits. Yet, clinically non-invasive treatments rely on systemic drugs and are incapable of targeting desired brain areas and circuits specifically with chemical precision. Prof. Yanik and his team recently developed a novel technology for non-invasive focal hyperconcentrated drug delivery to the brain circuits using focused ultrasound (external page https://www.nature.com/articles/s41467-020-18059-7). While this technology's intense development has been supported by ERC Consolidator award, the SNSF and Innosuisse now granted 2.2 Mio CHF towards clinical translation. Together with neurosurgeon Dr. Michael Hugelshofer's team (University Hospital Zurich), and veterinarian Dr. Henning Richter's team (Vetsuisse Faculty), Prof. Yanik’s team is working on demonstrating the efficacy and safety of this drug delivery technology in preclinical large-animal models.